LGI1 tumor tissue expression and serum autoantibodies in patients with primary malignant glioma

on behalf of the PERNO Study Group

Research output: Contribution to journalArticlepeer-review


Objectives: The Leucine-rich glioma inactivated 1 (LGI1) protein is thought to be implicated in malignant progression of glioma tumors, and mutations in the encoding gene, LGI1, cause autosomal dominant lateral temporal epilepsy, a genetic focal epilepsy syndrome. The aim of this study was to investigate the possible involvement of LGI1 in high-grade glioma-associated epilepsy by analyzing its expression in tumor specimens of patients with and without epilepsy and by searching for LGI1 autoantibodies in the sera these patients. Patients and methods: We examined tumor tissue samples from 24 patients with high-grade gliomas (12 with and 12 without epilepsy) by immunoblot and detected variable amounts of LGI1 in tumor tissues from 9/24 (37%) patients. Results: LGI1 was detected in 7/12 (58%) patients with epilepsy and in 2/12 (16%) patients without epilepsy (p = 0.0894; Fisher's exact test). Moreover, testing blood sera of five patients for antibodies against LGI1 revealed LGI1 autoantibodies in two patients, both suffering from epilepsy and expressing LGI1 in tumor tissue. Conclusion: Our findings suggest that there may be a preferential expression of LGI1 in high-grade glioma tumors of patients with epilepsy. We also unveil the presence of serum LGI1 autoantibodies in some patients with high-grade gliomas, where they might play an epileptogenic role.

Original languageEnglish
Pages (from-to)27-33
Number of pages7
JournalClinical Neurology and Neurosurgery
Publication statusPublished - Jul 1 2018


  • Epilepsy
  • GB
  • Glioblastoma
  • High-grade glioma
  • LGI1 autoantibodies

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology


Dive into the research topics of 'LGI1 tumor tissue expression and serum autoantibodies in patients with primary malignant glioma'. Together they form a unique fingerprint.

Cite this